In a wave of new data on amylin agonists, it's becoming clear that the interest in these drugs is all about tolerability. Zealand, Roche, @elilillyandcompany.bsky.social, @novonordisk.bsky.social & others are making bets on this class of drugs.
conscienhealth.org/2026/06/07/a...
